Hepatic Disease in Patients With HIV
Summary
- HCV infection does not significantly alter the virologic or immunologic response to effective antiretroviral therapy[Miller 2005] Adverse Events
- Interferon- and ribavirin-free DAA regimens recommended for the treatment of HCV infection in patients coinfected with HIV have shown to be highly tolerable with generally favorable safety profiles
- The most important safety consideration for HCV therapy in patients with HCV/HIV coinfection are established and potential drug–drug interactions between HCV DAAs and antiretroviral agents
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content